UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period

Quality of life research, 2023-07, Vol.32 (7), p.2047-2058

2023

Volltextzugriff (PDF)

Optimizing Dosing of Oncology Drugs

Clinical pharmacology and therapeutics, 2014-11, Vol.96 (5), p.572-579

2014

Volltextzugriff (PDF)

A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

Annals of oncology, 2018-10, Vol.29, p.viii334-viii334

2018

Volltextzugriff (PDF)

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions

British journal of cancer, 2013-08, Vol.109 (4), p.1072-1078

2013

Volltextzugriff (PDF)

The generalizability of NCI-sponsored clinical trials accrual amongst women with gynecologic malignancies

Gynecologic oncology, 2016-06, Vol.141, p.14-15

2016

Volltextzugriff (PDF)

Postoperative complications and survivorship trends following ovarian cancer surgery in New York state

Gynecologic oncology, 2017-06, Vol.145, p.168-168

2017

Volltextzugriff (PDF)

Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE ® to Provide Two Distinct and Complementary Perspectives

Patient related outcome measures, 2022-01, Vol.13, p.249-258

2022

Volltextzugriff (PDF)

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

British journal of cancer, 2010-02, Vol.102 (3), p.495-499

2010

Volltextzugriff (PDF)

Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

The New England journal of medicine, 2004-05, Vol.350 (22), p.2239-2246

2004

Volltextzugriff (PDF)

Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials

JNCI : Journal of the National Cancer Institute, 2014-07, Vol.106 (7), p.dju129-dju129

2014

Volltextzugriff (PDF)

Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT +) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062)

Gynecologic oncology, 2013-07, Vol.130 (1), p.e11-e11

2013

Volltextzugriff (PDF)

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)

JNCI : Journal of the National Cancer Institute, 2014-09, Vol.106 (9), p.dju244-dju244

2014

Volltextzugriff (PDF)

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

Journal of clinical oncology, 1993-07, Vol.11 (7), p.1368-1375

1993

Volltextzugriff (PDF)

Earthquake rupture process recreated from a natural fault surface

Journal of geophysical research. Solid earth, 2015-11, Vol.120 (11), p.7852-7862

2015

Volltextzugriff (PDF)

1755PD - Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events

Annals of oncology, 2019-10, Vol.30, p.v718-v719

2019

Volltextzugriff (PDF)

Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events

Annals of oncology, 2019-10, Vol.30, p.v718-v719

2019

Volltextzugriff (PDF)

1755PDImplementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Primary debulking surgery versus neoadjuvant chemotherapy in elderly patients with epithelial ovarian cancer

Gynecologic oncology, 2018-06, Vol.149, p.78-78

2018

Volltextzugriff (PDF)

Accrual to clinical trials: let's look at the physicians

JNCI : Journal of the National Cancer Institute, 2011-03, Vol.103 (5), p.357-358

2011

Volltextzugriff (PDF)

936PDA phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Prevention and Early Detection Clinical Trials: Opportunities for Primary Care Providers and Their Patients

CA: a cancer journal for clinicians, 2003-03, Vol.53 (2), p.82-101

2003

Volltextzugriff (PDF)

Abstract P1-15-01: Final analysis of SWOG S0230/Prevention of early menopause study (POEMS)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-15-01

2018

Volltextzugriff (PDF)

Introduction

Journal of the National Cancer Institute. Monographs, 2007-10, Vol.2007 (37), p.1-4

2007

Volltextzugriff (PDF)

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

JNCI : Journal of the National Cancer Institute, 2005-01, Vol.97 (2), p.94-102

2005

Volltextzugriff (PDF)

1 – 25 von 334

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(306)
Mit Volltextzugriff
(267)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(172)
Humans
(139)
Life Sciences & Biomedicine
(137)
Oncology
(84)
Female
(65)
Male
(59)
Middle Aged
(55)
Aged
(43)
Biological And Medical Sciences
(42)
Adult
(40)
Medical Sciences
(40)
Clinical Trials
(33)
Physical Sciences
(32)
Animals
(30)
Tumors
(30)
Treatment Outcome
(26)
United States
(25)
Cancer
(19)
Chemistry
(18)
Prostatic Neoplasms - Prevention & Control
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period

Optimizing Dosing of Oncology Drugs

A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions

The generalizability of NCI-sponsored clinical trials accrual amongst women with gynecologic malignancies

Postoperative complications and survivorship trends following ovarian cancer surgery in New York state

Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE ® to Provide Two Distinct and Complementary Perspectives

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials

Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT +) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062)

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

Prevention and early detection of prostate cancer

Earthquake rupture process recreated from a natural fault surface

1755PD - Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events

Implementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events

1755PDImplementation of PRO-CTCAE in phase I clinical trials identifies under reporting of adverse events

Primary debulking surgery versus neoadjuvant chemotherapy in elderly patients with epithelial ovarian cancer

Accrual to clinical trials: let's look at the physicians

936PDA phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

Prevention and Early Detection Clinical Trials: Opportunities for Primary Care Providers and Their Patients

Abstract P1-15-01: Final analysis of SWOG S0230/Prevention of early menopause study (POEMS)

Introduction

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Suchergebnisse filtern